Evidence map›Paper›PMID 31067706›Full record

Trial reportNutrients2019

Monitoring Vitamin B

Antonio Mastroianni, Chiara Maura Ciniselli, Rossella Panella, Alessandra Macciotta, Adalberto Cavalleri, Elisabetta Venturelli, Francesca Taverna, Arabella Mazzocchi, Eleonora Bruno, Paola Muti and 4 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrients, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Vitamin BFrontiers in nutrition · 2025
    Article
  2. Review
  3. Article
  4. Metformin - a new approach.Pediatric endocrinology, diabetes, and metabolism · 2021
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Antonio MastroianniLaboratory Medicine-Department of Pathology and Laboratory Medicine, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy. antonio.mastroianni@istitutotumori.mi.it.
Chiara Maura CiniselliBioinformatics and Biostatistics Unit-Department of Applied Research and Technological Development, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy. chiara.ciniselli@istitutotumori.mi.it.
Rossella PanellaLaboratory Medicine-Department of Pathology and Laboratory Medicine, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy. rossella.panella@istitutotumori.mi.it.
Alessandra MacciottaBioinformatics and Biostatistics Unit-Department of Applied Research and Technological Development, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy. alessandra.macciotta@istitutotumori.mi.it.
Adalberto CavalleriEpidemiology and Prevention Unit-Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy. adalberto.cavaller@istitutotumori.mi.it.
Elisabetta VenturelliEpidemiology and Prevention Unit-Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy. elisabetta.venturelli@istitutotumori.mi.it.
Francesca TavernaImmunohematology and Transfusion Medicine Service-Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy. francesca.taverna@istitutotumori.mi.it.
Arabella MazzocchiEpidemiology and Prevention Unit-Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy. arabella.mazzocchi@istitutotumori.mi.it.
Eleonora BrunoEpidemiology and Prevention Unit-Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy. eleonora.bruno@istitutotumori.mi.it.
Paola MutiChair Cancer Experimental Therapeutics, Department of Oncology Faculty of Health Science, McMaster University, Hamilton, ON L8V 1C3, Canada. muti@mcmaster.ca.
Franco BerrinoEpidemiology and Prevention Unit-Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy. franco.berrino@istitutotumori.mi.it.
Paolo VerderioBioinformatics and Biostatistics Unit-Department of Applied Research and Technological Development, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy. paolo.verderio@istitutotumori.mi.it.
Daniele MorelliLaboratory Medicine-Department of Pathology and Laboratory Medicine, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy. daniele.morelli@istitutotumori.mi.it.
Patrizia PasanisiEpidemiology and Prevention Unit-Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy. patrizia.pasanisi@istitutotumori.mi.it.ORCID 0000-0001-6278-3491
Fondazione IRCCS Istituto Nazionale dei Tumori · ITMcMaster University · CA

Funding

European Research Council ERC-ADG-2012-322752
6 · The paper itself

Abstract

Metformin (MET) is currently being used in several trials for cancer prevention or treatment in non-diabetics. However, long-term MET use in diabetics is associated with lower serum levels of total vitamin B

Indexed as

AgedBreast NeoplasmsDiet, MediterraneanFemaleHumansHypoglycemic AgentsMetforminMethylmalonic AcidMiddle AgedPilot ProjectsRisk FactorsTranscobalaminsVitamin B 12Vitamin B 12 DeficiencyHypoglycemic AgentsMetforminMethylmalonic AcidTranscobalaminsVitamin B 12holotranscobalamin IImetforminmethylmalonic acidvitamin B12

Identifiers

PMID31067706
PMCPMC6567263
OpenAlexW2944068496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.